摘要
背景:阿尔茨海默病(AD)是最广泛的年龄相关的神经变性疾病。最近,越来越多的证据表明植物化学用减缓AD的发病和进展。 目的:回顾植物化学对AD治疗的潜在作用。 方法:从现有文献中对用于治疗AD患者的植物化学物质进行系统评价。选择标准包括:1)年龄≥60岁; 2)AD诊断符合国家老年痴呆症协会(NIAAA)的标准,3)适当的措施来评估认知功能和临床状态。 结果:本研究共纳入97篇文章。几种植物化学物质似乎减缓AD发作,延缓疾病进展,并通过抗胆碱能,抗氧化和抗炎功能来针对多种病理原因进行恢复。 结论:植物化学物质及其特定分子靶点的深入了解对于保证安全使用这些化合物作为AD治疗的选择至关重要。
关键词: 植物化学物质,阿尔茨海默病,抗氧化性能,抗炎活性,乙酰胆碱酯酶抑制剂,AChEIs
图形摘要
Current Drug Targets
Title:Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review
Volume: 18 Issue: 13
关键词: 植物化学物质,阿尔茨海默病,抗氧化性能,抗炎活性,乙酰胆碱酯酶抑制剂,AChEIs
摘要: Background: Alzheimer's disease (AD) is the most widespread age-related neurodegenerative disease. Recently, a growing body of evidence suggested the phytochemical use to slow down AD onset and progression.
Objective: To review the phytochemical role potentially involved in AD treatment. Method: A systematic review from existing literature on phytochemicals used in the treatment of AD patients was conducted. Selection criteria included: 1) age≥60 years; 2) AD diagnosis in agreement with the criteria of National Institute on Aging-Alzheimer's Association (NIAAA), and 3) suitable measures to asses cognitive, functional and clinical status. Results: Ninety-seven articles were involved in the present study. Several phytochemicals seem to slow down AD onset, delay disease progression and let recovery through targeting multiple pathological causes by anti-cholinergic, antioxidant and anti-inflammatory features. Conclusion: Deeper knowledge on phytochemicals and their specific molecular targets is essential to guarantee safe use of these compounds as an option for AD treatment.Export Options
About this article
Cite this article as:
Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review, Current Drug Targets 2017; 18 (13) . https://dx.doi.org/10.2174/1389450117666161102121553
DOI https://dx.doi.org/10.2174/1389450117666161102121553 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Physiology and Therapeutics of Vascular Endothelial Growth Factor in Tumor Immunosuppression
Current Molecular Medicine New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit
Current Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy
Current Pharmaceutical Design Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties
Endocrine, Metabolic & Immune Disorders - Drug Targets Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Antioxidants in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology New Hybrid Scaffolds based on Hydrazinyl Thiazole Substituted Coumarin; As Novel Leads of Dual Potential; In Vitro α-Amylase Inhibitory and Antioxidant (DPPH and ABTS Radical Scavenging) Activities
Medicinal Chemistry